SUPERNUS PHARMACEUTICALS INC (SUPN)
US8684591089 - Common Stock
Overall SUPN gets a fundamental rating of 6 out of 10. We evaluated SUPN against 197 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of SUPN get a neutral evaluation. Nothing too spectacular is happening here. SUPN is valued quite cheap, while showing a decent growth score. This is a good combination! This makes SUPN very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year SUPN was profitable.
In the past year SUPN had a positive cash flow from operations.
SUPN had positive earnings in each of the past 5 years.
In the past 5 years SUPN always reported a positive cash flow from operatings.
1.2 Ratios
SUPN has a better Return On Assets (-1.19%) than 82.05% of its industry peers.
The Return On Equity of SUPN (-1.67%) is better than 83.59% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.52%, SUPN is in the better half of the industry, outperforming 77.44% of the companies in the same industry.
SUPN had an Average Return On Invested Capital over the past 3 years of 3.33%. This is significantly below the industry average of 17.16%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.19% | ||
| ROE | -1.67% | ||
| ROIC | 0.52% |
ROA(3y)2.28%
ROA(5y)5%
ROE(3y)4.51%
ROE(5y)9.92%
ROIC(3y)3.33%
ROIC(5y)6.63%
1.3 Margins
SUPN's Profit Margin has declined in the last couple of years.
SUPN's Operating Margin of 1.09% is fine compared to the rest of the industry. SUPN outperforms 77.95% of its industry peers.
SUPN's Operating Margin has declined in the last couple of years.
SUPN has a better Gross Margin (87.17%) than 89.74% of its industry peers.
SUPN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.09% | ||
| PM (TTM) | N/A | ||
| GM | 87.17% |
OM growth 3Y-58.75%
OM growth 5Y-41.33%
PM growth 3Y-79.29%
PM growth 5Y-61.95%
GM growth 3Y-1.39%
GM growth 5Y-2.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SUPN has more shares outstanding
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 3.76 indicates that SUPN is not in any danger for bankruptcy at the moment.
SUPN has a Altman-Z score of 3.76. This is in the better half of the industry: SUPN outperforms 78.46% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.76 |
ROIC/WACC0.06
WACC8.1%
2.3 Liquidity
A Current Ratio of 1.73 indicates that SUPN should not have too much problems paying its short term obligations.
The Current ratio of SUPN (1.73) is worse than 71.28% of its industry peers.
A Quick Ratio of 1.49 indicates that SUPN should not have too much problems paying its short term obligations.
SUPN's Quick ratio of 1.49 is on the low side compared to the rest of the industry. SUPN is outperformed by 70.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.93% over the past year.
SUPN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.43% yearly.
The Revenue for SUPN has decreased by -10.64% in the past year. This is quite bad
Measured over the past years, SUPN shows a quite strong growth in Revenue. The Revenue has been growing by 8.24% on average per year.
EPS 1Y (TTM)53.93%
EPS 3Y-15.98%
EPS 5Y-7.43%
EPS growth Q2Q-10.34%
Revenue 1Y (TTM)-10.64%
Revenue growth 3Y5.3%
Revenue growth 5Y8.24%
Revenue growth Q2Q-6.58%
3.2 Future
Based on estimates for the next years, SUPN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.98% on average per year.
The Revenue is expected to grow by 6.43% on average over the next years.
EPS Next Y19.24%
EPS Next 2Y19.09%
EPS Next 3Y26.88%
EPS Next 5Y28.98%
Revenue Next Year0.83%
Revenue Next 2Y1.94%
Revenue Next 3Y5.16%
Revenue Next 5Y6.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 21.24, which indicates a rather expensive current valuation of SUPN.
84.62% of the companies in the same industry are more expensive than SUPN, based on the Price/Earnings ratio.
SUPN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.15.
SUPN is valuated correctly with a Price/Forward Earnings ratio of 14.66.
SUPN's Price/Forward Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 83.59% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.20, SUPN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.24 | ||
| Fwd PE | 14.66 |
4.2 Price Multiples
83.08% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 86.15% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.94 | ||
| EV/EBITDA | 11.62 |
4.3 Compensation for Growth
SUPN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
SUPN has a very decent profitability rating, which may justify a higher PE ratio.
SUPN's earnings are expected to grow with 26.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.1
PEG (5Y)N/A
EPS Next 2Y19.09%
EPS Next 3Y26.88%
5. Dividend
5.1 Amount
SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SUPERNUS PHARMACEUTICALS INC
NASDAQ:SUPN (5/17/2024, 7:00:01 PM)
After market: 29.1 0 (0%)29.1
-0.06 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.59B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.24 | ||
| Fwd PE | 14.66 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.1
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.19% | ||
| ROE | -1.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 1.09% | ||
| PM (TTM) | N/A | ||
| GM | 87.17% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.49 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)53.93%
EPS 3Y-15.98%
EPS 5Y
EPS growth Q2Q
EPS Next Y19.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-10.64%
Revenue growth 3Y5.3%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y